Askenazi, David
,
Abitbol, Carolyn
Boohaker, Louis
Griffin, Russell
Raina, Rupesh
Dower, Joshua
Davis, T. Keefe
Ray, Patricio E.
Perazzo, Sofia
DeFreitas, Marissa
Milner, Lawrence
Ambalavanan, Namasivayam
Cole, F. Sessions
Rademacher, Erin
Zappitelli, Michael
Mhanna, Maroun
Article History
Received: 28 June 2018
Revised: 6 November 2018
Accepted: 24 November 2018
First Online: 13 December 2018
Ethics Committee Approval
: The University of Alabama at Birmingham Institutional Review Board (IRB) approved this collaborative study, and each center received approval from their respective IRBs.
: All authors declare no real or perceived conflicts of interest that could affect the study design, collection, analysis and interpretation of data, writing of the report, or the decision to submit for publication. For full disclosure, we provide here an additional list of other author’s commitments and funding sources that are not directly related to this study: David J Askenazi serves on the speaker board for Baxter (Baxter, USA), and the Acute Kidney Injury (AKI) Foundation (Cincinnati, OH, USA); he also receives grant funding for studies not related to this manuscript from National Institutes of Health—National Institutes of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK, R01 DK103608 and NIH-FDA, R01 FD005092). Jennifer G Jetton is supported by the University of Iowa Institute for Clinical and Translational Sciences NIH U54TR001356. Juan C. Kupferman is on the speaker’s Bureau and consultant for Alexion Pharmaceuticals. Robert Woroniecki is supported by the Department of Pediatrics at Stony Brook Children’s hospital (NY, USA). AWAKEN investigators at the Canberra Hospital were supported by the Canberra Hospital Private Practice fund, and investigators at University of Virginia Children’s Hospital were supported by a 100 Women Who Care Grant (100 Women Charitable Foundation, CA, USA).